Subsequent events (Details) - USD ($) |
Mar. 06, 2023 |
Dec. 31, 2022 |
|---|---|---|
| Subsequent events. | TCR2 Therapeutics | ||
| Ownership percentage | 25.00% | |
| Subsequent events. | Adaptimmune | ||
| Ownership percentage | 75.00% | |
| Astellas Collaboration Agreement | ||
| Amount of remaining deferred income under the collaboration that had not been recognized as revenue | $ 43,070,000 | |
| Astellas Collaboration Agreement | Subsequent events. | ||
| Amount of termination penalties in connection with the termination. | $ 0 |
| X | ||||||||||
- Definition Amount of termination penalties in connection with the termination. No definition available.
|
| X | ||||||||||
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|